Hearing aid support for patients with DR-TB in Ethiopia

• Published in: Public health action 2022-06, Vol.12 (2), p.74-78
• Main Authors: Teferra, G, Teklemariam, K, Wares, D. F., Negeri, C., Bedru, A.
• Format: Article
• Language: English
• Subjects: Bedaquiline Introduction; Challenge Tb; Drug-Resistant-Tb; Original
• ISSN: 2220-8372; 2220-8372
• DOI: 10.5588/pha.21.0068

SETTING: Previous and current patients with drug-resistant TB (DR-TB) who had documented treatment-related hearing impairment due to second-line injectable (SLI) use were identified from different DR-TB treatment initiation centres in Ethiopia.OBJECTIVE: To assess selected patients with DR-TB for eligibility for hearing aids and provide hearing aids to 10 eligible patients.DESIGN: This was an observational cohort study. Patients were followed up for 8 months, with hearing assessments conducted at 1, 3 and 8 months to objectively assess hearing capacity.RESULTS: Of 12 patients assessed for hearing aids eligibility, 10 were fitted with hearing aids (type XTM XP P4) and followed up for 8 months. "Formal" improvement was observed only in one patient. However, "general quality of life" appeared to be improved in nine patients.CONCLUSION: Minimal "formal" improvement was observed. However, the study was too small to say whether hearing aids should, or should not, be recommended as a public health measure. This needs a larger better controlled follow-up study. The all-oral DR-TB treatment regimens should be used for all patients with DR-TB in Ethiopia. However, as a proportion of patients with DR-TB are likely to continue receiving SLIs in the foreseeable future, they will require close audiometry assessment and appropriate care.